Annual report pursuant to Section 13 and 15(d)

License, Clinical Trial and Sponsored Research Agreements (Tables)

v3.23.1
License, Clinical Trial and Sponsored Research Agreements (Tables)
12 Months Ended
Dec. 31, 2022
License Agreements [Member]  
License, Clinical Trial and Sponsored Research Agreements  
Schedule of Clinical Trial and Sponsored Research Agreements

For the years ended December 31, 2022 and 2021, the Company recorded the following expense in research and development for licenses acquired:

​

​

​

​

​

​

​

​

​

​

For the year ended December 31, 

($ in thousands)

    

2022

    

2021

City of Hope National Medical Center

​

​

​

​

​

​

CD123

​

$

—

​

$

250

IV/ICV

​

​

125

​

​

—

PSCA

​

​

—

​

​

250

HER2

​

​

200

​

​

—

CSL Behring (Calimmune)

​

​

40

​

​

30

Leiden University Medical Centre

​

​

—

​

​

350

Mayo Clinic

​

​

—

​

​

750

Fortress PIK Dividend

​

​

1,109

​

​

4,212

Total

​

$

1,474

​

$

5,842

​

Sponsored Research and Clinical Trial Agreements [Member]  
License, Clinical Trial and Sponsored Research Agreements  
Schedule of Clinical Trial and Sponsored Research Agreements

For the year ended December 31, 2022 and 2021, the Company recorded the following expense in research and development for sponsored research and clinical trial agreements:

​

​

​

​

​

​

​

​

​

​

For the year ended December 31, 

($ in thousands)

    

2022

    

2021

City of Hope National Medical Center

​

$

—

​

$

—

CD123

​

​

166

​

​

301

IL13Rα2

​

​

1,486

​

​

1,169

CS1

​

​

482

​

​

608

HER2

​

​

784

​

​

697

PSCA

​

​

103

​

​

107

Fred Hutchinson Cancer Center - CD20

​

​

1,987

​

​

1,979

St. Jude Children's Research Hospital - XSCID

​

​

508

​

​

865

LUMC - RAG1 SCID

​

​

505

​

​

170

Mayo Clinic

​

​

968

​

​

695

Total

​

$

6,989

​

$

6,591

​